共 101 条
[11]
Brahmer JR(2008)Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin Cancer Res 14 3044-3051
[12]
Tykodi SS(2014)Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial Lancet Oncol. 15 69-77
[13]
Chow LQ(2009)B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders Blood 114 2149-2158
[14]
Topalian SL(2006)Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma Blood 107 3639-3646
[15]
Hodi FS(2010)Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma Blood. 116 3268-3277
[16]
Brahmer JR(2007)The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma Proc Natl Acad Sci USA 104 13134-13139
[17]
Lipson EJ(2011)MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers Nature 471 377-381
[18]
Sharfman WH(2012)Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and post transplant lymphoproliferative disorders: implications for targeted therapy Clin Cancer Res 18 1611-1618
[19]
Drake CG(2002)Approach to Hodgkin’s lymphoma in the new millennium Hematol Oncol 20 1-15
[20]
Taube JM(2015)PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma N Engl J Med 372 311-319